Safety and tolerability of FOLFIRABRAX [5-Fluourouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced gastrointestinal (GI) cancer patients (pts): A multicenter trial of the University of Chicago Personalized Cancer Care Consortium.

Smita Suhas Joshi,Theodore Karrison,Daniel V.T. Catenacci,Jaclyn D Peterson,Mark M. Zalupski,Brooke Elizabeth Phillips,Ahad A. Sadiq,Amikar Sehdev,James L. Wade,Vincent J. Picozzi,Andrea Louise Amico,Robert Marsh,Mark Kozloff,Blase N. Polite,Hedy L. Kindler,Manish Sharma

Safety and tolerability of FOLFIRABRAX [5-Fluourouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced gastrointestinal (GI) cancer patients (pts): A multicenter trial of the University of Chicago Personalized Cancer Care Consortium.

2018

Smita Suhas Joshi
Theodore Karrison
Daniel V.T. Catenacci
Jaclyn D Peterson
Mark M. Zalupski
Brooke Elizabeth Phillips
Ahad A. Sadiq
Amikar Sehdev
James L. Wade
Vincent J. Picozzi
Andrea Louise Amico
Robert Marsh
Mark Kozloff
Blase N. Polite
Hedy L. Kindler
Manish Sharma

e16241Background: 5-FU, IRI, and NP are active in GI cancers; the combination, FOLFIRABRAX, has not been evaluated. UGT1A1 clears SN-38, the active metabolite of IRI. UGT1A1*28 polymorphism reduces...

Keywords:

Nab-paclitaxel
Dosing
Oncology
Cancer
Multicenter trial
Pathology
Genotype
Irinotecan
Tolerability
Medicine
Internal medicine
gi cancer
Active metabolite

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations